Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M16,556Revenue $M2,877Net Margin (%)-25.1Z-Score1.1
Enterprise Value $M20,538EPS $-4.9Operating Margin %-31.2F-Score4
P/E(ttm))0Cash Flow Per Share $7.2Pre-tax Margin (%)-39.1Higher ROA y-yN
Price/Book6.110-y EBITDA Growth Rate %0Quick Ratio0.9Cash flow > EarningsY
Price/Sales4.85-y EBITDA Growth Rate %0Current Ratio1.1Lower Leverage y-yY
Price/Cash Flow3.9y-y EBITDA Growth Rate %0ROA % (ttm)-7.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-32.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M178ROI % (ttm)-16.6Gross Margin Increase y-yN

Gurus Latest Trades with ENDP

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ENDPGeorge Soros 2014-12-31 Buy 1.4%$60.19 - $73.37
($68.57)
$ 93.2726%New holding1,748,729
ENDPJulian Robertson 2014-12-31 Sold Out -0.37%$60.19 - $73.37
($68.57)
$ 93.2726%Sold Out0
ENDPJoel Greenblatt 2014-12-31 Sold Out -0.01%$60.19 - $73.37
($68.57)
$ 93.2726%Sold Out0
ENDPWallace Weitz 2014-09-30 Reduce-0.34%$61.26 - $70.27
($65.73)
$ 93.2730%Reduce -17.65%721,950
ENDPJoel Greenblatt 2014-09-30 Reduce-0.07%$61.26 - $70.27
($65.73)
$ 93.2730%Reduce -84.54%13,716
ENDPSteve Mandel 2014-06-30 Sold Out -1.2%$56.28 - $73.94
($66.81)
$ 93.2728%Sold Out0
ENDPWallace Weitz 2014-06-30 Add0.81%$56.28 - $73.94
($66.81)
$ 93.2728%Add 75.01%876,670
ENDPGeorge Soros 2014-06-30 Sold Out -0.13%$56.28 - $73.94
($66.81)
$ 93.2728%Sold Out0
ENDPJoel Greenblatt 2014-06-30 Buy 0.08%$56.28 - $73.94
($66.81)
$ 93.2728%New holding88,697
ENDPMario Gabelli 2014-06-30 Reduce$56.28 - $73.94
($66.81)
$ 93.2728%Reduce -21.77%23,900
ENDPJoel Greenblatt 2014-03-31 Sold Out -0.64%$64.3 - $81.49
($70.78)
$ 93.2724%Sold Out0
ENDPJulian Robertson 2014-03-31 Buy 0.51%$64.3 - $81.49
($70.78)
$ 93.2724%New holding22,800
ENDPGeorge Soros 2014-03-31 Buy 0.13%$64.3 - $81.49
($70.78)
$ 93.2724%New holding198,503
ENDPWallace Weitz 2014-03-31 Add0.12%$64.3 - $81.49
($70.78)
$ 93.2724%Add 12.33%500,920
ENDPDavid Dreman 2014-03-31 Sold Out -0.01%$64.3 - $81.49
($70.78)
$ 93.2724%Sold Out0
ENDPSteve Mandel 2013-12-31 Buy 1.3%$43.64 - $67.25
($57.05)
$ 93.2739%New holding4,340,000
ENDPWallace Weitz 2013-12-31 Buy 1%$43.64 - $67.25
($57.05)
$ 93.2739%New holding445,920
ENDPJoel Greenblatt 2013-12-31 Reduce-0.18%$43.64 - $67.25
($57.05)
$ 93.2739%Reduce -23.94%397,016
ENDPDavid Dreman 2013-12-31 Buy 0.01%$43.64 - $67.25
($57.05)
$ 93.2739%New holding1,378
ENDPJoel Greenblatt 2013-09-30 Add0.12%$36.3 - $45.61
($40.18)
$ 93.2757%Add 18.50%521,987
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ENDP is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ENDP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MANOGUE CAROLINE BExec. V.P.,Chief Legal Officer 2015-04-08Sell105,562$91.92.37view
Farhat CamillePresident, AMS, Inc. 2015-03-10Sell8,650$89.395.25view
Farhat CamillePresident, AMS, Inc. 2015-03-09Sell40,438$87.028.11view
MANOGUE CAROLINE BExec. V.P.,Chief Legal Officer 2015-03-05Sell42,033$87.787.18view
Lortie BrianPresident Branded Pharma 2015-03-04Sell5,800$85.3510.23view
Upadhyay SuketuEVP, CFO 2014-11-14Buy3,700$66.9440.54view
HIGGINS ARTHUR JDirector 2014-08-05Buy3,500$65.6543.31view
DELUCCA JOHNDirector 2014-06-09Sell6,764$68.8336.68view
MANOGUE CAROLINE BExec. V.P., CLO & Secy 2014-05-29Sell175,033$72.0230.63view
DELUCCA JOHNDirector 2014-05-01Sell8,094$66.3141.88view

Press Releases about ENDP :

    Quarterly/Annual Reports about ENDP:

    News about ENDP:

    Articles On GuruFocus.com
    Weitz Value Fund First Quarter 2015 Commentary Apr 20 2015 
    Weekly Insider Sells Highlight: ANTM, ENDP, QVCA, TOL Apr 12 2015 
    Valeant Finally Bags Salix for $11 Billion Apr 06 2015 
    This Week’s Pharma Highlights Mar 19 2015 
    Valeant Pharmaceuticals Goes Aggressive To Win Over Salix Mar 18 2015 
    Valeant Pharma Acquires Salix Mar 18 2015 
    Endo International Shares Upbeat After Positive Q4 Earnings Report Mar 03 2015 
    Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
    George Soros' Top New Holdings Feb 18 2015 
    Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 


    More From Other Websites
    DepoMed Set To Grow On 'Transformative' Nucynta Deal Apr 23 2015
    Shire Gets Dropped from AQR Capital’s Portfolio Apr 23 2015
    Will the Salix-Valeant story play out over and over again? Apr 23 2015
    Meet Pharma’s Newest Movers and Shakers Apr 22 2015
    Lone Pine Reduces Its Stake in Valeant Pharmaceuticals Apr 22 2015
    Morgan Stanley US drug sector note predicts 'no M&S slowdown' Apr 21 2015
    OZ Management’s New Positions in 4Q14 Apr 20 2015
    Autohome, Other Foreign Stock Leaders Seen Posting Big Q1 Apr 13 2015
    Permian Investment Partners Has A Thing or Two To Teach You About Investing Apr 10 2015
    Endo International plc (ENDP), BioMarin Pharmaceutical Inc. (BMRN): Visium Picks Returned 13% but... Apr 10 2015
    Tiger Ratan Trumps Hedge Fund Industry in Q1; See How Nehal Chopra’s Stock Picks Performed Apr 10 2015
    Billionaire John Griffin’s Five Picks That Killed the Market This Quarter Apr 09 2015
    What's Next For The Thousands Of Angry Men Suing Over Testosterone? Apr 06 2015
    3 JPMorgan Bull Calls Hitting The Market Apr 02 2015
    These 10 Pharma and Health Care Stocks Were the Best S&P 500 Performers Last Quarter Apr 02 2015
    Drugmaker Valeant completes $11 billion purchase of Salix Apr 01 2015
    Valeant closes $11B deal for Raleigh's Salix Pharmaceuticals Apr 01 2015
    BioDelivery Slumps, Diabetic Pain Gel Fails Phase III Study - Analyst Blog Mar 31 2015
    Can Boston Scientific Keep Its Turnaround Gains Going? Mar 30 2015
    Hyperion Could Be Next Pharma Target With Orphan Drugs: Real M&A Mar 28 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK